anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To improve the nutrient and taste of the subject polysaccharide in high efficiency by adding an inorganic acid, etc., to an aqueous solution of a roasted dextrin, etc., heating under pressure, neutralizing the product and reacting with a saccharifying amylase. CONSTITUTION:Starch such as tapioca starch is added with 0.2-0.5wt.% of an inorganic acid such as HCl, heated under normal pressure at about 120 deg.C for about 30min, neutralized and reacted with glucoamylase, etc., to obtain a roasted dextrin aqueous solution (A) containing about 50wt.% of glucose based on the starch. The component A is heated at 120-140 deg.C for about 20min as it is (pH2.3) or after adjusting the pH to about 1.8 with an inorganic acid or an organic acid. The decomposition of the hardly digestible polysaccharide part is proceeded by this process to obtain an acid-saccharified liquid (B). The component B is reacted with glucoamylase to obtain a saccharified liquid (E) containing glucose (C) (a digestible sugar) and a hardly digestible polysaccharide (D) in mixed state. The component E is fractionated by passing through a get- filtration layer to remove the component C and the filtrate is decolored and purified with activated carbon and an ion exchange resin to produce the objective hardly digestible polysaccharide.
Daily oral doses of adrenergic blocker 5 mg or 10 mg. The dosage will be gradually increased from the initial recommended starting dose of 1 mg daily at bedtime and titrated stepwise to 2mg, 5mg or 10 mg weekly, according to patient tolerability, as measured by subjective complaints, arterial blood pressure and heart rate. The target dose will be 5 mg or 10 mg daily based on subject's tolerability.
The number of individuals with gender incongruence who present to their physician for hormone therapy has increased manifold in the last decade. Testosterone therapy in transgender men (also known as female-to-male transgender or transmen) and estrogen therapy in transgender women (also known as male-to-female transgender or transwomen) respectively is the mainstay of hormone regimen.Transwomen, who are genetically men, receive estradiol replacement with the aim of suppressing serum testosterone and achieving serum estradiol concentrations that mimic the serum concentrations of biological women. This leads to an increase in fat mass, breast growth and decreases in lean mass and masculine pattern hair. However, the results of these changes are often less than satisfactory and additional therapy is required.

Breast development is a major concern for transgender females. There is a great deal of variability among individuals, as evidenced during pubertal development.Transgender women do not achieve the same level of breast development as cisgender women do after puberty. Typically, transgender women plateau at Tanner stage III and half of the transgender women have a AAA cup size or less.Investigators plan to conduct a randomized, placebo controlled double blind study evaluating the effect of adding progesterone for 6 months to transwomen who are being treated with estradiol. The hypothesis is that progesterone will decrease serum testosterone concentrations as compared to placebo and increase breast size. Investigators will also assess its role in mood, sleep, scalp hair and androgenic hair growth.
Albuminuria is characterized by a disruption of the glomerular filtration barrier, which is composed of the fenestrated endothelium, the glomerular basement membrane, and the slit diaphragm. Nephrin is a major component of the slit diaphragm. Apart from hemodynamic effects, Ang II enhances albuminuria by β-Arrestin2-mediated nephrin endocytosis. Blocking the AT1 receptor with candesartan and irbesartan reduces the Ang II-mediated nephrin-β-Arrestin2 interaction. The inhibition of MAPK ERK 1/2 blocks Ang II-enhanced nephrin-β-Arrestin2 binding. ERK 1/2 signaling, which follows AT1 receptor activation, is mediated by G-protein signaling, EGFR transactivation, and β-Arrestin2 recruitment. A mutant AT1 receptor defective in EGFR transactivation and β-Arrestin2 recruitment reduces the Ang II-mediated increase in nephrin β-Arrestin2 binding. The mutation of β-Arrestin2K11,K12, critical for AT1 receptor binding, completely abrogates the interaction with nephrin, independent of Ang II stimulation. β-Arrestin2K11R,K12R does not influence nephrin cell surface expression. The data presented here deepen our molecular understanding of a blood-pressure-independent molecular mechanism of AT-1 receptor blockers (ARBs) in reducing albuminuria.
It is aimed that an artificial intelligence-based mobile application that includes information, nutrition, exercise programs, complications and medication tracking, personalized suggestions, alarms and reminders, which will enable diabetic individuals to follow their glucose targets, support patients in their diabetes education, awareness and disease management to continue more actively. In addition, it is aimed that patients can easily access information, prevent acute and chronic complications, present physical activity and nutrition suggestions in accordance with the person\'s lifestyle, follow up on medications with alarms and reminders, prevent the negative results of complications in advance, and improve individuals\' diabetes-specific knowledge levels, compliance with treatment, self-management and care with information and guidance about foot care to reduce the risk of diabetic feet, which is particularly risky for diabetic patients.
System and method for monitoring hand hygiene of a user. The system includes a handheld electronic device for being carried by the user to generate device data such as location data. A portable dispenser assembly is worn by the user to dispense disinfectant fluid from a container in a plurality of dispensing events. The assembly includes an electronics unit that generates event data relating to the dispensing events. The assembly is separate from the handheld electronic device yet configured to communicate with the handheld electronic device. A monitoring system receives the device data and the event data relating to the dispensing events for evaluating the hand hygiene of the user.
The treatment group will receive 100 units of BOTOX® reconstituted in 10mL of injectable preservative-free normal saline at the time of cystoscopy. An injection cystoscopy needle will be set to 3mm and used to inject 0.5mL reconstituted OnabotulinumtoxinA at each injection site, approximately 1cm apart along the posterior bladder wall, for a total of 20 injection sites (4 rows of 5 injection sites). This will be the only treatment.
Neighborhood conditions can positively impact mental health and wellbeing. Green space has been cited as a potential buffer between inequitable neighborhood conditions and poor health. However, there is limited evidence how to increase exposure to green space and how much exposure is needed to produce benefit. Place-based and person-based interventions offer contrasting approaches to improving the impact of the environment on health. The environment influences people as they traverse the spaces between home, work, and recreation, in ways that can be healthy or harmful. Place-based approaches directly change the environment to encourage healthy behaviors, and potentially have broad population impact. Alternatively, person-based approaches directly target individuals' behavior and may be more feasible. To our knowledge, no studies combine both approaches into a single intervention, which may be more effective over either alone.

The broad objectives of this proposal are to pilot test two intervention strategies to increase green space use- place-based and person-based, as well as evaluate the dose-response relationship between green space use and health. Our place-based intervention, Nature Nooks, builds on our prior greening treatment by adding new features to encourage use - a path and benches to invite people into the space and instillation on large corner lots to maximize visibility. The investigators develop our person-based intervention, Nature Coach, as a novel adoption of an analogous, established patient navigator concept in healthcare.
Patients will be dual scanned; one with 4D-CT in free-breathing and one wearing the compression belt.Organ motion will then be quantified using Eclipse. This facilitates a direct comparison to determine the efficacy of the compression belt. Patients with reduction in organ motion will be treated wearing the abdominal compression belt. The alignment scale will be recorded to facilitate accurate placement each fraction. The belt will be inflated to a tolerable level by the patient and recorded for consistency each fraction. The position of the belt will be referenced to the anterior and lateral tattoos to ensure accurate and consistent placement each fraction.
Participants enrolled in this cohort will receive venetoclax ramp-up to 400 mg orally (as background therapy) starting on Cycle 1 Day 1 and followed by 400 mg daily dosing starting on Cycle 1 Day 4 plus cusatuzumab IV on Day 3 and Day 17 of each 28-day cycle. Cohort 2 will not be enrolled in the US.
<P>PROBLEM TO BE SOLVED: To support information input of an electronic medical chart in continuous medical examination when creating the electronic medical chart.  <P>SOLUTION: A tool set registration part 28 stores a set of information input tools used for medical chart creation into a tool set master table 14 together with a disease name/consultation contents. When creating an medical chart of an accepted patient, an accepted patient reference part 21 acquires consultation contents from an acceptance information table 17, and a patient's disease name reference part 23 acquires a disease name and an outcome from a patients' disease name table 16. A tool set reference part 24 searches for tool set information agreeing with the disease name and the consultation contents in continuous examination from the tool set master table 14 and acquires tool set contents. A medical chart creation part 22 expands a patient's medical chart, and a tool starting part 25 starts respective tools of tool set contents so that they can be expanded for medical chart creation processing, A medical chart storage part 26 stores the created medical chart into a chart data table 15.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Cerebral amyloid angiopathy-related inflammation (CAA-ri) is a rapid but reversible autoimmune encephalopathy where spontaneous autoantibody reaction against amyloid beta deposited in cerebral blood vessels produces characteristic neuroinflammatory changes such as vasogenic edema and microhemorrhages on MRI. The term amyloid-related imaging abnormalities (ARIA) is sometimes used to describe these changes but are more often reserved for similar MRI signal abnormalities seen after administration of anti-amyloid immunotherapy, using treatment exposure as an antecedent. It is unclear if there is any biological basis for this dichotomized distinction. We report a case of severe CAA-ri after exposure to SARS-CoV-2 vaccine and performed a literature review of CAA-ri related to vaccination. CAA-ri precipitated by immunogenic triggers other than anti-amyloid therapy would lend support to the hypothesis that ARIA seen on MRI may represent the same disease underpinned by a shared anti-Aβ autoantibody response irrespective of etiology. A thorough history should be taken before labelling CAA-ri as spontaneous.
OBJECTIVE: Current risk algorithms do not accurately predict cardiovascular disease (CVD) risk in rheumatoid arthritis (RA). An area of interest is that of single-nucleotide polymorphisms (SNPs), of which several have been associated with CVD in the general population. We investigated whether these SNPs are associated with CVD in RA and whether SNPs could improve CVD risk prediction in RA.
METHODS: Sixty SNPs were genotyped in 353 patients with RA. Logistic and Cox regression analyses were performed to identify SNPs that were associated with CVD (n = 99). A prediction model with clinical variables was made. SNPs were added to investigate the additional predictive value. Both models were internally validated. External validation was done in a separate cohort (n = 297).
RESULTS: rs3184504, rs4773144, rs12190287, and rs445925 were significantly associated with new CVD. The clinical prediction model consisted of age, sex, body mass index, systolic blood pressure, high-density lipoprotein cholesterol (HDLc), and creatinine, with an area under the curve (AUC) of 0.74 (P = 0.03). Internal validation resulted in an AUC of 0.76 (P < 0.01). A new model was made including SNPs and resulted in a model with rs17011666 and rs801426, age, total cholesterol, and HDLc, which performed slightly better with an AUC of 0.77 (P < 0.01). External validation resulted in a good fit for the clinical model, but a poor fit for the SNP model.
CONCLUSION: Several SNPs were associated with CVD in RA. Risk prediction slightly improved after adding SNPs to the models, but the clinical relevance is debatable. However, larger studies are needed to determine more accurately the additional value of these SNPs to CVD risk prediction algorithms.
Subjects are tracked and not treated for their MRSA. If the subject reaches a protocol defined exacerbation within the first 28 days then they will be treated per choice of their primary Pulmonologist.
Epinephrine, due to its alpha-1 and beta-adrenergic effects, is considered an important part of the management of children with hypo-tension. Epinephrine is typically used as a continuous infusion (0.02-0.5 μg/kg/min) for severe sustained hypo-tension and as a bolus (0.01 mg/kg, maximum dose = 1 mg) for bradycardia, asystole, or pulse-less arrest. There are, however, clinical conditions that may benefit from smaller doses of bolus epinephrine. For example, brief periods of hypo-tension during medical procedures, intermittent hemodynamic instability, and augmentation of low blood pressure in a pre-arrest condition. While a resuscitation (or code) dose of epinephrine would be inappropriate (as it would cause an unacceptable large increase in blood pressure and heart rate \[HR\]), a smaller dose may be particularly useful.

Low-dose bolus vasopressors have been used for decades by anaesthesiologists to prevent post-re-perfusion injury after solid organ transplant, control cerebral oxygenation during anaesthesia and manage acute hypo-tension during spinal surgery. Recently, use of bolus dose phenyl-ephrine has been described in the emergency department setting to augment blood pressure during periods of hypo-tension surrounding intubation. Finally, free open access medical publications have provided some insight into using bolus dose pressors for acute hypotensive episodes in adults. However, there is few published data describing the use of low-dose vasopressor boluses in children.
PROBLEM TO BE SOLVED: To obtain a cosmetic excellent in skin lightening effect such as reduction in tyrosinase activity of coloring matter cell, moisture retaining effect, hardly emitting an unpleasant smell, comprising an extract prepared by deodorizing a dried substance of a sea alga and extracting the dried substance. SOLUTION: This cosmetic comprises preferably >=0.01 pt.wt. calculated as a solid content of an extract prepared by deodorizing a dried substance of a sea alga (preferably Ulva pertusa) and extracting the dried substance based on 100 pts.wt. of the cosmetic. The dried substance of the sea alga is preferably deodorized by using 5-10 pts.wt. based on 100 pts.wt. of the dried substance of the sea alga of activated carbon of coconut husk or activated soil as a deodorant at 30-60 deg.C for 2-4 hours. The deodorized sea alga is preferably extracted by using purified water or ethanol. When the extraction is carried out, for example, at pH5-8 at 20 deg.C, the time required for the extraction is preferably 1-7 days. The objective cosmetic may be mixed with various cosmetic components such as an excipient, a perfume, oils and fats, a humectant, a skin lightening agent, an ultraviolet absorber.
This study investigates the genetic factors contributing to the disparity in prostate cancer incidence and progression among African American men (AAM) compared to European American men (EAM). The research focuses on employing Weighted Gene Co-expression Network Analysis (WGCNA) on public microarray data obtained from prostate cancer patients. The study employed WGCNA to identify clusters of genes with correlated expression patterns, which were then analyzed for their connection to population backgrounds. Additionally, pathway enrichment analysis was conducted to understand the significance of the identified gene modules in prostate cancer pathways. The Least Absolute Shrinkage and Selection Operator (LASSO) and Correlation-based Feature Selection (CFS) methods were utilized for selection of biomarker genes. The results revealed 353 differentially expressed genes (DEGs) between AAM and EAM. Six significant gene expression modules were identified through WGCNA, showing varying degrees of correlation with prostate cancer. LASSO and CFS methods pinpointed critical genes, as well as six common genes between both approaches, which are indicative of their vital role in the disease. The XGBoost classifier validated these findings, achieving satisfactory prediction accuracy. Genes such as APRT, CCL2, BEX2, MGC26963, and PLAU were identified as key genes significantly associated with cancer progression. In conclusion, the research underlines the importance of incorporating AAM and EAM population diversity in genomic studies, particularly in cancer research. In addition, the study highlights the effectiveness of integrating machine learning techniques with gene expression analysis as a robust methodology for identifying critical genes in cancer research.
The present invention discloses a hybrid metal-lipid nanoparticle for targeted therapy comprising properties of organic and inorganic nanoparticles (NPs), combined in a single formulation to obtain NPs with unique attributes. This will allow the synergistic effect between drug delivery (also known as chemotherapy) and photothermal therapy. This strategy relies on the construction of hybrid metallic- gold nanoparticles using a dual functionality by lipid nanoparticles (as organic components and drug delivery system) in the core and gold nanorods (as inorganic component and a heat delivery system) in the shell, linked by a tumor-targeting peptide. The active targeting strategy was implemented to guarantee a specific delivery to the brain by using transferrin (targeting the blood-brain barrier) and c[RGDfK] (not only used to target GB tumor barrier but also as a linker between both inorganic and organic nanoparticles). The invention relates to the field of medicine and biotechnology. The present solution aims at developing targeting hybrid metal-lipid nanoparticle for the treatment of different types of cancer, including glioblastoma, envisioning the establishment of an in vitro/in vivo correlation.
Patients with coccydynia will receive 10 sessions of physical therapy, 5 days a week for 2 weeks. Intermittent ultrasound will be used as a physical therapy agent. Intermittent ultrasound treatment will be applied to the muscles of the bilateral coccyx region at a dose of 1.0W/cm², at a frequency of 1 Megahertz, for 3+3 minutes.
The present invention relates to pharmaceutical compositions containing at least one of hydantoin derivatives as hypoglycemic as well as hypolipidemic agents. The present invention is based on the selection of a hydantoin which is bonded by a sulfonyl group to various substituents at the 1 - position of the hydantoin skeleton. The compounds of the present invention represent a satisfactory hypoglycemic as well as hypolipidemic activity. These compounds are extremely useful for the treatment and/or prevention of diabetes mellitus with or without hyperlipidemia. It is indicated that the compounds of the present invention are useful for the treatment and/or prevention of diabetic complications such as somatic or autonomic neuropathy, cataract, retinopathy, nephropathy or microangiopathy. It is also indicated that the compounds of the present invention are useful for the treatment and/or prevention of hyperlipidemia.
FIELD: methods for human hairs. SUBSTANCE: method involves contact of human hairs on which decolorizing composition is applied. It comprises, at least, one oxidizing agent with gas containing water steam. Temperature of gas is higher 75 C, contact duration between gas and hairs is not more 10 min. EFFECT: reduced coloring time. 13 cl
Factor VIII activity assays are used to diagnose hemophilia A, to monitor treatment of these patients, to determine when inhibitory antibodies against factor VIII have developed, and to evaluate the activity of engineered pharmaceutical factor VIII products. Factor VIII activity has been measured with one and two-stage assays for more than fifty years. However, all existing assays have major shortcomings that are recognized by the FDA, the International Society for Thrombosis and Haemostasis, and pharmaceutical companies. The major deficiencies that have been identified are: 1) Factor VIII activity levels do not predict the risk of bleeding in patients with inhibitory antibodies. The degree of inhibition in these assays is less than required to explain patient bleeding. 2) The assays are only accurate over a range of 1 - 100% of normal factor VIII activity, while values of 0.1 - 1% are also clinically important. 3) The different approved assays give discrepant values for recombinant pharmaceutical factor VIII products, with a range of 2-fold difference between assays. This can lead to clinically important differences in dosing of factor VIII products from one region to another with corresponding risk of thrombosis or bleeding.

The preliminary data identify an additional deficiency of commercial assays that has not been anticipated. Commercial one and two-stage assays may not detect some clinically significant inhibitor antibodies. Thus, the purpose of the proposed studies is to standardize and validate a platelet-based factor VIII activity assay with greater sensitivity to clinically important inhibitory antibodies.
PURPOSE:To obtain an antiserum containing an anti-phenylmustard compound antibody useful for the remedy of cancer, by immunizing a warm-blooded animal with a protein, immunizing further with a bonded product of a phenylmustard compound and a protein and collecting the blood from said warm-blooded animal. CONSTITUTION:A warm-blooded animal is immunized with a protein and then further immunized at least once with a bonded product of the protein and a compound of formula [R1 is CH=CH or CH2-CH(NH2); R2 is H or alkyl; n is 0-2], e.g. p-[di(2-chloroethyl)amino]-L-phenylalanine, to preferentially produce the antibody against the above compound. Blood is collected from the immunized warm-blooded animal and the supernatant is separated by centrifugal separation, etc., to obtain the objective antiserum. The above bonded product and the antibody against the protein are preferably removed from the antiserum. The compound of formula is infused to a cancer tissue or its neighbor, and the above antiserum is administered to effect the specific reaction of the compound of formula with the antibody against said compound and break the cancer tissue.
This study is an observational study to assess FOG via using multiple methods such as: clinical features, imaging, cognition and dopamine blood levels. The study consists of four parts (plus an optional fifth part) that will be completed over two-three separate days within a 30 day span. The four parts will not necessarily be performed in this order. Part one will be clinical and written questionnaire assessments of PD and FOG followed by 3D motion capture evaluations. Part two are cognitive or neuropsychiatric assessments. Part three is a magnetic resonance image (MRI) to examine the brain structure. Part four is Positron Emission Tomography (PET) imaging scan that measures norepinephrine transporter levels. The optional part 5 is a lumbar puncture that will measure cerebrospinal fluid catecholamines and proteomics.